Tumor apoptosis in prostate cancer by PGD2 and its metabolite 15d-PGJ2 in murine model

Biomedicine and Pharmacotherapy

Volumn 67, Issue 1, 2013, Pages 66-71

  Nakamura, Masaki ^a   Tsumura, Hideyasu ^b   Satoh, Takefumi ^b   Matsumoto, Kazumasa ^b   Maruyama, Hiroko ^c   Majima, Masataka ^a,b   Kitasato, Hidero ^a,c  

^a KITASATO UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^b KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c KITASATO UNIVERSITY   (Japan)

Author keywords

15d PGJ2; Apoptosis; Prostate cancer

Indexed keywords

ANTINEOPLASTIC AGENT; PROSTAGLANDIN D2 DERIVATIVE; RETROVIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DRUG SCREENING; ENZYME LINKED IMMUNOSORBENT ASSAY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENETIC VECTORS; IN SITU NICK-END LABELING; INTRAMOLECULAR OXIDOREDUCTASES; LIPOCALINS; MALE; MICE; MICE, INBRED C57BL; PROSTAGLANDIN D2; PROSTATIC NEOPLASMS; RETROVIRIDAE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSFECTION;

EID: 84873087775     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2012.10.012     Document Type: Article

References (29)

1. Ricciotti E., Fitzgerald G.A. Prostaglandins and inflammation. Arterioscler Thromb Vasc Biol 2011, 31:986-1000.
2. Simmons D.L., Botting R.M., Hla T. Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol Rev 2004, 56:387-437.
3. Kanaoka Y., Fujimori K., Kikuno R., Sakaguchi Y., Urade Y., Hayaishi O. Structure and chromosomal localization of human and mouse genes for hematopoietic prostaglandin D synthase. Conservation of the ancestral genomic structure of sigma-class glutathione S-transferase. Eur J Biochem 2000, 267:3315-3322.
4. Urade Y., Hayaishi O. Biochemical, structural, genetic, physiological, and pathophysiological features of lipocalin-type prostaglandin D synthase. Biochim Biophys Acta 2000, 1482:259-271.
5. Hayaishi O. Molecular genetic studies on sleep-wake regulation, with special emphasis on the prostaglandin D(2) system. J Appl Physiol 2002, 92:863-868.
6. Forman B.M., Tontonoz P., Chen J., Brun R.P., Spiegelman B.M., Evans R.M. 15-Deoxy-delta 12,14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell 1995, 83:803-812.
7. Scher J.U., Pillinger M.H. 15d-PGJ2: the anti-inflammatory prostaglandin?. Clin Immunol 2005, 114:100-109.
8. Sato H., Ishihara S., Kawashima K., Moriyama N., Suetsugu H., Kazumori H., et al. Expression of peroxisome proliferator-activated receptor (PPAR)gamma in gastric cancer and inhibitory effects of PPARgamma agonists. Br J Cancer 2000, 83:1394-1400.
9. Tsubouchi Y., Sano H., Kawahito Y., Mukai S., Yamada R., Kohno M., et al. Inhibition of human lung cancer cell growth by the peroxisome proliferator-activated receptor-gamma agonists through induction of apoptosis. Biochem Biophys Res Commun 2000, 270:400-405.
10. Shimada T., Kojima K., Yoshiura K., Hiraishi H., Terano A. Characteristics of the peroxisome proliferator activated receptor gamma (PPARgamma) ligand induced apoptosis in colon cancer cells. Gut 2002, 50:658-664.
11. Patel L., Pass I., Coxon P., Downes C.P., Smith S.A., Macphee C.H. Tumor suppressor and anti-inflammatory actions of PPARgamma agonists are mediated via upregulation of PTEN. Curr Biol 2001, 11:764-768.
12. Sawano H., Haneda M., Sugimoto T., Inoki K., Koya D., Kikkawa R. 15-Deoxy-Delta12,14-prostaglandin J2 inhibits IL-1beta-induced cyclooxygenase-2 expression in mesangial cells. Kidney Int 2002, 61:1957-1967.
13. Chaffer C.L., Thomas D.M., Thompson E.W., Williams E.D. PPARgamma-independent induction of growth arrest and apoptosis in prostate and bladder carcinoma. BMC Cancer 2006, 6:53.
14. Satoh T., Toyoda M., Hoshino H., Monden T., Yamada M., Shimizu H., et al. Activation of peroxisome proliferator-activated receptor-gamma stimulates the growth arrest and DNA-damage inducible 153 gene in non-small cell lung carcinoma cells. Oncogene 2002, 21:2171-2180.
15. Shiau C.W., Yang C.C., Kulp S.K., Chen K.F., Chen C.S., Huang J.W., et al. Thiazolidenediones mediate apoptosis in prostate cancer cells in part through inhibition of Bcl-xL/Bcl-2 functions independently of PPARgamma. Cancer Res 2005, 65:1561-1569.
16. Clay C.E., Monjazeb A., Thorburn J., Chilton F.H., High K.P. 15-Deoxy-delta12,14-prostaglandin J2-induced apoptosis does not require PPARgamma in breast cancer cells. J Lipid Res 2002, 43:1818-1828.
17. Ohta K., Endo T., Haraguchi K., Hershman J.M., Onaya T. Ligands for peroxisome proliferator-activated receptor gamma inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells. J Clin Endocrinol Metab 2001, 86:2170-2177.
18. Liu T., Laurell C., Selivanova G., Lundeberg J., Nilsson P., Wiman K.G. Hypoxia induces p53-dependent transactivation and Fas/CD95-dependent apoptosis. Cell Death Differ 2007, 14:411-421.
19. Selvakumaran M., Yao K.S., Feldman M.D., O'Dwyer P.J. Antitumor effect of the angiogenesis inhibitor bevacizumab is dependent on susceptibility of tumors to hypoxia-induced apoptosis. Biochem Pharmacol 2008, 75:627-638.
20. Polikandriotis J.A., Mazzella L.J., Rupnow H.L., Hart C.M. Peroxisome proliferator-activated receptor gamma ligands stimulate endothelial nitric oxide production through distinct peroxisome proliferator-activated receptor gamma-dependent mechanisms. Arterioscler Thromb Vasc Biol 2005, 25:1810-1816.
21. Murata T., Lin M.I., Aritake K., Matsumoto S., Narumiya S., Ozaki H., et al. Role of prostaglandin D2 receptor DP as a suppressor of tumor hyperpermeability and angiogenesis in vivo. Proc Natl Acad Sci U S A 2008, 105:20009-20014.
22. Murata T., Aritake K., Matsumoto S., Kamauchi S., Nakagawa T., Hori M., et al. Prostagladin D2 is a mast cell-derived antiangiogenic factor in lung carcinoma. Proc Natl Acad Sci U S A 2011, 108:19802-19807.
23. Xin X., Yang S., Kowalski J., Gerritsen M.E. Peroxisome proliferator-activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo. J Biol Chem 1999, 274:9116-9121.
24. Mendez M., LaPointe M.C. PPARgamma inhibition of cyclooxygenase-2, PGE2 synthase, and inducible nitric oxide synthase in cardiac myocytes. Hypertension 2003, 42:844-850.
25. Greenhough A., Smartt H.J., Moore A.E., Roberts H.R., Williams A.C., Paraskeva C., et al. The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis 2009, 30:377-386.
26. Mohammed S.I., Bennett P.F., Craig B.A., Glickman N.W., Mutsaers A.J., Snyder P.W., et al. Effects of the cyclooxygenase inhibitor, piroxicam, on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer. Cancer Res 2002, 62:356-358.
27. Caughey G.E., Cleland L.G., Penglis P.S., Gamble J.R., James M.J. Roles of cyclooxygenase (COX)-1 and COX-2 in prostanoid production by human endothelial cells: selective up-regulation of prostacyclin synthesis by COX-2. J Immunol 2001, 167:2831-2838.
28. Aggarwal B.B., Shishodia S., Sandur S.K., Pandey M.K., Sethi G. Inflammation and cancer: how hot is the link?. Biochem Pharmacol 2006, 72:1605-1621.
29. Ricote M., Li A.C., Willson T.M., Kelly C.J., Glass C.K. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 1998, 391:79-82.